| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Investigations |
James Ewing Laboratory of Developmental Hematopoiesis, Memorial Sloan-Kettering Cancer Center [M. E., K. M., P. D., M. A. S. M.]; and New York Presbyterian Hospital-Weill Medical College of Cornell University, [R. T. S.] New York, New York 10021
We studied telomerase regulation and telomere length in hematopoietic progenitor cells from peripheral blood and bone marrow from patients with acute and chronic leukemia and myeloproliferative diseases. CD34+ cells from a total of 93 patients with either acute myeloid leukemia (AML; n = 25), chronic myeloid leukemia (CML; n = 21), chronic lymphocytic leukemia (CLL; n = 18), polycythemia vera (PV; n = 16), or myelodysplastic syndromes (MDS; n = 13) were analyzed before and in 19 patients after ex vivo expansion in the presence of multiple cytokines (kit ligand, interleukin-3, interleukin-6, and granulocyte colony-stimulating factor plus erythropoietin). Compared with hematopoietic progenitor cells from normal donors (n = 108), telomerase activity (TA) was increased 2- to 5-fold in chronic phase (CP)-CML, CLL, PV, and MDS. In AML, accelerated phase (AP) and blastic phase (BP)-CML, basal TA was 10- to 50-fold higher than normal. TA of CP-CML CD34+ cells was up-regulated within 72 h of ex vivo culture, peaked after 1 week, and decreased below detection after 2 weeks. In contrast, TA in AP/BP-CML and AML CD34+ cells was down-regulated after 1 week of culture and decreased further thereafter. The expansion potential of CD34+ cells from patients with leukemia was considerably decreased compared with CD34+ cells from normal donors. The average expansion of cells from leukemic individuals was 6.5-, 2.3-, 0.6-, and 0.2-fold in weeks 1, 2, 3, and 4, respectively, whereas expansion of normal cells was 5- to 15-fold higher. In serial expansion culture, a median telomeric loss of 0.7 kbp was observed during 3–4 weeks of expansion. Our results demonstrate that up-regulation of telomerase is similar in CD34+ cells from CP-CML, CLL, PV, and MDS patients and in normal hematopoietic cells during the first week of culture, whereas in AML and AP/BP-CML, telomerase is high at baseline and down-regulated during expansion culture. High levels of telomerase in leukemic progenitors at baseline may be a feature of both the malignant phenotype and rapid cycling. Telomerase down-regulation during culture of leukemic cells may be due to the decreased expansion potential or repression of normal hematopoiesis, or in AML it may be due to the partial differentiation of AML cells, shown previously to be associated with loss of TA. Telomere shortening during ex vivo expansion correlated with low levels of TA, particularly in chronic leukemic and MDS progenitors where telomerase was insufficient to protect against telomere bp loss during intense proliferation.
This article has been cited by other articles:
|
|
 |
|
  S. H. Ghaffari, N. Shayan-Asl, A. H. Jamialahmadi, K. Alimoghaddam, and A. Ghavamzadeh Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival Ann. Onc., November 1, 2008; 19(11): 1927 - 1934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Drummond, S. Balabanov, T. L. Holyoake, and T. H. Brummendorf Concise Review: Telomere Biology in Normal and Leukemic Hematopoietic Stem Cells Stem Cells, August 1, 2007; 25(8): 1853 - 1861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jaras, A. Edqvist, J. Rebetz, L. G. Salford, B. Widegren, and X. Fan Human short-term repopulating cells have enhanced telomerase reverse transcriptase expression Blood, August 1, 2006; 108(3): 1084 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Beyne-Rauzy, N. Prade-Houdellier, C. Demur, C. Recher, J. Ayel, G. Laurent, and V. Mansat-De Mas Tumor necrosis factor-{alpha} inhibits hTERT gene expression in human myeloid normal and leukemic cells Blood, November 1, 2005; 106(9): 3200 - 3205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Ferraris, R. Mangerini, N. Pujic, O. Racchi, D. Rapezzi, A. Gallamini, S. Casciaro, and G. F. Gaetani High telomerase activity in granulocytes from clonal polycythemia vera and essential thrombocythemia Blood, March 1, 2005; 105(5): 2138 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gammaitoni, K. C. Weisel, M. Gunetti, K.-D. Wu, S. Bruno, S. Pinelli, A. Bonati, M. Aglietta, M. A. S. Moore, and W. Piacibello Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication Blood, June 15, 2004; 103(12): 4440 - 4448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-D. Wu, L. M. Orme, J. Shaughnessy Jr, J. Jacobson, B. Barlogie, and M. A. S. Moore Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival Blood, June 15, 2003; 101(12): 4982 - 4989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sashida, J. H. Ohyashiki, A. Nakajima, M. Sumi, K. Kawakubo, T. Tauchi, and K. Ohyashiki Telomere Dynamics in Myelodysplastic Syndrome Determined by Telomere Measurement of Marrow Metaphases Clin. Cancer Res., April 1, 2003; 9(4): 1489 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Maesawa, T. Inaba, H. Sato, S. Iijima, K. Ishida, M. Terashima, R. Sato, M. Suzuki, A. Yashima, S. Ogasawara, et al. A rapid biosensor chip assay for measuring of telomerase activity using surface plasmon resonance Nucleic Acids Res., January 15, 2003; 31(2): e4 - e4. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Thornley and M. H. Freedman Telomeres, X-Inactivation Ratios, and Hematopoietic Stem Cell Transplantation in Humans: A Review Stem Cells, May 1, 2002; 20(3): 198 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Korbling and P. Anderlini Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood, November 15, 2001; 98(10): 2900 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. J. Elenitoba-Johnson Complex Regulation of Telomerase Activity : Implications for Cancer Therapy Am. J. Pathol., August 1, 2001; 159(2): 405 - 410. [Full Text]
|
|
|
|
|
|
M. Engelhardt, J. Finke, N. Rufer, T. H. Brummendorf, B. Chapuis, C. Helg, P. M. Lansdorp, and E. Roosnek Does telomere shortening count? Blood, August 1, 2001; 98(3): 888 - 890. [Full Text] [PDF]
|
|
|
|
|
|
O. Bruserud, G. Tjønnfjord, B. T. Gjertsen, B. Foss, and P. Ernst New Strategies in the Treatment of Acute Myelogenous Leukemia: Mobilization and Transplantation of Autologous Peripheral Blood Stem Cells in Adult Patients Stem Cells, September 1, 2000; 18(5): 343 - 351. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
